Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT

被引:52
作者
deBont, DBA
Leenders, RGG
Haisma, HJ
vanderMeulenMuileman, I
Scheeren, HW
机构
[1] CATHOLIC UNIV NIJMEGEN,NSR CTR MOL STRUCT DESIGN & SYNTH,DEPT ORGAN CHEM,NL-6525 ED NIJMEGEN,NETHERLANDS
[2] FREE UNIV AMSTERDAM,ACAD HOSP,DEPT MED ONCOL,NL-1081 HV AMSTERDAM,NETHERLANDS
关键词
D O I
10.1016/S0968-0896(96)00249-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The syntheses of prodrugs of paclitaxel, which can be used in ADEPT in order to target paclitaxel towards tumor cells, are described. The prodrugs 1 and 2a,b consist of a spacer molecule connected via a carbamate linkage to a beta-glucuronic acid. The spacer molecule is also connected via an ester linkage to the 2'-OH of paclitaxel. Enzyme-catalyzed hydrolysis of the glucuronic acid moiety by human beta-glucuronidase results in the liberation of the parent drug paclitaxel via gamma or delta lactam formation with half-lives of 45 min and 2h (1 and 2h). The prodrugs 1 and 2b are two orders of magnitude less cytotoxic than paclitaxel. (C) 1997, Elsevier Science Ltd.
引用
收藏
页码:405 / 414
页数:10
相关论文
共 49 条
[1]   ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - A REVIEW [J].
BAGSHAWE, KD .
DRUG DEVELOPMENT RESEARCH, 1995, 34 (02) :220-230
[2]   ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY [J].
BAGSHAWE, KD .
CLINICAL PHARMACOKINETICS, 1994, 27 (05) :368-376
[3]   ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) [J].
BAGSHAWE, KD .
JOURNAL OF CONTROLLED RELEASE, 1994, 28 (1-3) :187-193
[4]  
BOSSLET K, 1994, CANCER RES, V54, P2151
[5]  
BUNDGAARD H, 1991, Drugs of the Future, V16, P443
[6]  
CHEN SH, 1995, CHEM PHARM TAXOL ITS, P165
[7]   SYNTHESIS OF CONGENERS AND PRODRUGS .3. WATER-SOLUBLE PRODRUGS OF TAXOL WITH POTENT ANTITUMOR-ACTIVITY [J].
DEUTSCH, HM ;
GLINSKI, JA ;
HERNANDEZ, M ;
HAUGWITZ, RD ;
NARAYANAN, VL ;
SUFFNESS, M ;
ZALKOW, LH .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (04) :788-792
[8]  
EDWARDS DP, 1986, CANCER RES, V46, P1306
[9]  
GEORG GI, 1995, TAXOL SCI APPL, P317
[10]  
GESSON JP, 1994, ANTI-CANCER DRUG DES, V9, P409